西维斯健康（CVS）今日盘前交易时段股价大跌5.18%，回吐了早前因业绩超预期带来的涨幅，引发市场关注。
消息面上，尽管公司此前公布的二季度业绩好于预期并上调了全年盈利指引，但随后一位高管坦言，预计2027年340B药品折扣计划带来的市场压力将持续发酵，并对药房服务业务构成显著拖累。这一表态令投资者对公司的中长期盈利前景产生担忧。
此外，西维斯健康在发布业绩的同时也重申了对年内剩余时间的谨慎立场，表示在成本趋势持续攀升以及宏观经济逆风可能加剧的背景下，核心业务增长或将受到抑制。分析人士指出，若通胀或劳动力市场波动加剧，公司盈利能力可能进一步承压，这在一定程度上抵消了业绩超预期的积极影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.